Baxter International Inc ( (BAX) ) has released its Q2 earnings. Here is a breakdown of the information Baxter International Inc presented to its investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Baxter International Inc. is a global leader in medical technology, providing essential healthcare solutions including medical devices and pharmaceuticals. The company operates in the medical products and therapies sector and is known for its commitment to innovation and healthcare delivery.
In the second quarter of 2025, Baxter International Inc. reported a 4% increase in sales from continuing operations, reaching $2.81 billion. The company’s earnings per share (EPS) from continuing operations were $0.24 on a GAAP basis and $0.59 on an adjusted basis, aligning with prior guidance. A significant leadership change was announced with Andrew Hider set to take over as CEO, aiming to drive innovation and growth.
Key financial highlights include a 3% increase in U.S. sales and a 6% increase in international sales. The Medical Products & Therapies segment saw flat sales, while Healthcare Systems & Technologies and Pharmaceuticals segments experienced growth. Adjusted net income from continuing operations rose by 28% compared to the previous year.
Looking forward, Baxter expects full-year 2025 sales growth of 6% to 7% on a reported basis and adjusted earnings per share between $2.42 and $2.52. The company remains focused on enhancing operational effectiveness and creating shareholder value under new leadership.